By creator to www.prnewswire.com
LUND, Sweden, Could 20, 2020 /PRNewswire/ — Hansa Biopharma, the chief in immunomodulatory enzyme know-how for uncommon IgG mediated illnesses, in the present day introduced that the Firm’s novel IgG-degrading enzyme, imlifidase, will probably be highlighted in three displays together with a late breaking poster presentation on the upcoming 2020 American Transplant Congress (ATC), on Could 30 to June 1, 2020.
The ATC will probably be moved to an all-virtual format and all displays will probably be accessible in an on-demand format. The late breaking poster, “Observe up of imlifidase (IdeS) desensitized kidney transplant recipients” will probably be introduced by Dr. Christian Kjellman, CSO & COO at Hansa Biopharma within the class: Posters – Kidney Immunosuppression – Desensitization.
The poster will spotlight the two-year follow-up knowledge on 31 sufferers who acquired kidney transplantation after desensitization with imlifidase. The info display affected person and graft survival charges of 90% after remedy. 92% of the sufferers with knowledge had a passable or good kidney operate at 2 years with a median eGFR at 61.5 ml/min. As well as, the presentation elaborates on antibody mediated rejection (AMR) episodes in addition to the dynamics of donor-specific antibodies (DSA) after transplantation.
Following imlifidase desensitization and kidney transplantation, the extent of DSA began to return between three and 14 days. In some sufferers DSA return was related to AMR. Early AMR (onset through the first month post-transplant) occurred in 28% of the crossmatch optimistic sufferers, whereas one other 10% had been recognized as late AMR. The AMR frequency was comparable with these reported in different research with much less sensitized sufferers in crossmatch optimistic sufferers, and just one AMR episode occurred later than six months after transplantation.
The oral displays, “The Influence of a Optimistic Crossmatch on KAS Sufferers and Organs” will probably be introduced by Joshua Lee, MD Senior Medical Science Liaison at Hansa Biopharma within the class: Kidney Deceased Donor Allocation II.
The presentation highlights that reallocating kidneys attributable to optimistic crossmatch impacts the refused organ by considerably growing chilly ischemia time and the eventual discard of roughly 25 kidneys yearly. Sufferers had been affected with longer ready instances and a major quantity ending up being delisted or dying.
The presentation concludes that applied sciences and therapies to scale back crossmatch-positive refusals might doubtlessly have a optimistic affect on sufferers and allocation.
A second oral presentation, “Anti-HLA IgM antibodies are unaffected by imlifidase (IdeS) remedy.” will probably be introduced by Anna Runström, Scientist at Hansa Biopharma within the class: Kidney Immunosuppression – Desensitization
The presentation highlights an evaluation on whether or not imlifidase has an impact on human anti-HLA IgM antibodies in sensitized sufferers with finish stage renal illness.
It’s demonstrated that the discount of anti-HLA IgM indicators, which was famous after imlifidase remedy in some sufferers, was not noticed in IgG-depleted sera. The excessive anti-HLA IgM indicators are more likely to be brought on by IgG-complexed IgM on the floor of HLA beads.
It’s concluded that Human IgM just isn’t cleaved by imlifidase, offering additional proof that imlifidase particularly cleaves solely IgG.
“I’m very happy to see that the excessive unmet medical want for transplantation of essentially the most sensitized sufferers is strongly acknowledged and that imlifidase is highlighted at this essential convention within the US,” says Christian Kjellman CSO and COO at Hansa Biopharma.
“We’re very enthusiastic about how imlifidase doubtlessly can enhance entry to transplantation and that the long-term follow-up knowledge is consistent with finest expectations on this group of difficult sufferers with a really excessive medical want.”
All abstracts and displays will probably be obtainable on the ATC homepage at http://www.atcmeeting.org
For additional data, please contact:
Klaus Sindahl, Head of Investor Relations
Cellular: +46 (0) 709-298 269
E-mail: [email protected]
This data was delivered to you by Cision http://news.cision.com
The next recordsdata can be found for obtain:
SOURCE Hansa Biopharma AB
— to www.prnewswire.com